Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DU-176b versus warfarin for stroke prevention in atrial fibrillation
ACTRN12609000132246Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised trial of edoxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Composite of stroke and systemic embolic event. Started Nov 2008; status: recruiting.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12609000132246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000132246.